Clinical Trials Browser

Phase 4 × Neoplasms × Hydroxymethylglutaryl-CoA Reductase Inhibitors × Clear all

NCT05976893 2023-08-04

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Phase 4 Unknown

Neoplasms, Atherosclerosis